New pill targets tough cancers with BRCA gene flaws
Disease control
Recruiting now
This early-phase study tests a new drug called FORX-428 in people with advanced solid tumors that have BRCA1/2 mutations or other DNA repair problems. The main goals are to find a safe dose and check for side effects. About 40 adults whose cancer has worsened after standard treat…
Phase: PHASE1 • Sponsor: FoRx Therapeutics AG • Aim: Disease control
Last updated May 15, 2026 11:54 UTC